Loading...
Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review).
Baxter, Mark A Petty, Russell D Swinson, Daniel Hall, Peter S O'Hanlon, Shane
Baxter, Mark A
Petty, Russell D
Swinson, Daniel
Hall, Peter S
O'Hanlon, Shane
Advisors
Editors
Other Contributors
Departments
Date
2021-03-24
Date Submitted
Keywords
advanced gastroesophageal cancer
Frailty
geriatric oncology
real‑world
reduced performance status
Frailty
geriatric oncology
real‑world
reduced performance status
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
ijo_58_5_5202_PDF.pdf
Adobe PDF, 360.7 KB
Alternative Titles
Publisher
Abstract
Gastroesophageal adenocarcinoma (GOA) is a disease of older people. Incidence is rising in the developed world and the majority of patients present with advanced disease. Based on clinical trial data, systemic chemotherapy in the advanced setting is associated with improvements in quality of life and survival. However, there is a recognised mismatch between trial populations and the patients encountered in clinical practice in terms of age, comorbidity and fitness. Appropriate patient selection is essential to safely deliver effective treatment. In this narrative review, we discuss the challenges faced by clinicians when assessing real‑world patients with advanced GOA for systemic therapy. We also highlight the importance of frailty screening and the current available evidence we can use to guide our management.
Language
en
Citation
ISSN
eISSN
1791-2423
ISBN
DOI
10.3892/ijo.2021.5202
PMID
33760115